The American College of Obstetricians and Gynecologists (ACOG) is recommending that men get tested for andrological diseases like androgynous (female-like) prostate cancer and bulimia nervosa.
The APA’s statement comes after a new report found that the number of men in the U.S. who suffer from these disorders is on the rise.
The number of new diagnoses for these conditions has quadrupled since 2012, according to the APA.
A 2015 study by the American Association of Sexuality Educators found that there were now more than 1.6 million men who have been diagnosed with androgen-dependent disorders, a new and highly aggressive form of prostate cancer that affects about 1 in 10 men.
“The most common androgenic prostate cancers among men are non-small cell lung cancer and basal cell carcinoma of the prostate,” said Dr. David W. Lipsky, director of the Division of Andrology at Columbia University’s School of Medicine.
“This is a highly aggressive androgyny condition, which means that a man with this cancer will likely have a lower testosterone level and an increased risk of prostate enlargement.”
According to the Centers for Disease Control and Prevention (CDC), men who experience symptoms of androgenetic alopecia are more likely to develop prostate cancer.
Linsley and his colleagues at the APAC examined data from the National Cancer Institute’s Surveillance, Epidemiology, End Results (SEER) Program from 2010 through 2015, which included men diagnosed with non-specific androgen receptor-positive androgen insensitivity syndrome (NAIS).
NAIS is a condition where a man is unable to produce the androgen necessary for testosterone production.
“We found that men who had NAIS were 2.6 times more likely than men who did not have NAIS to develop a lifetime diagnosis of androgastric cancer,” said Lipsley.
The men with NAIS are more than twice as likely to have a lifetime incidence of prostate androgenomas, compared to men with other types of androgens.
The researchers also found that more than half of the men with a lifetime NAIS diagnosis had at least one new prostate cancer diagnosis in the previous year.
The study found that a lifetime prevalence of prostate growth occurred for more than 4 in 10 of the diagnosed men.
This means that about one in five men who developed prostate cancer will experience some kind of growth of their prostate within the next 10 years.
“In the first half of 2020, there were approximately 1,600,000 new cases of non-selective androgen resistance (NSAR) diagnoses in the United States,” said co-author Dr. Mary Ann M. Dolan, MD, associate professor of medicine and vice president of medical services for the American College Health Association.
“NSAR is the most common type of NSAR in the country, and it is estimated that one in four men in America will develop NSAR at some point in their lives.
In fact, this new androgen sensitivity finding suggests that in many cases, the risk for developing NSAR may be greater than the risk of developing prostate cancer.”
The APAC also found a link between the andrologic syndrome and the development of breast cancer, but that study did not include data on prostate cancer, and Lipski said that further research is needed to fully understand the potential role of the androgenic syndrome in the development and progression of prostate, androgen and breast cancers.
The findings of this study are important to women who have had their lives disrupted by the male-to-female gender transition.
“Our study provides the first comprehensive assessment of the prevalence of andrology-related health problems in men and women who transitioned from male to female,” said lead author Dr. Rachel E. Fennelly, a gynecologist in the division of gynecologic oncology at the University of Maryland Medical Center.
“Although we can only speculate on the underlying cause of these problems, it is possible that there may be biological mechanisms that lead to a gender-based difference in the prevalence and risk of andrology-related diseases in men.”
Lipskin and his co-authors concluded that there is a need to develop and standardize criteria for diagnosing and treating male-typical prostate cancers.
This is the first report to evaluate the risk and incidence of andrologic disorders in men in this age group and to show that these disorders are associated with risk of both cancer and disease progression in both men and men of both sexes.
“While the andrology syndrome is common among men, the association between the disorder and both cancer progression and prostate cancer is less clear,” said Fennetta.
“To the best of our knowledge, this is the only study to date to examine androgen sensit